Connect with us

Technology

IDEXX Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis

Published

on

The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX’s Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes 

WESTBROOK, Maine, June 4, 2024 /CNW/ — IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine and feline patients suspected of pancreatitis. With the innovative load-and-go workflow of the Catalyst analyzers, the test can run effortlessly alongside chemistry profiles, leading to a faster path to diagnosis and enhanced patient outcomes. The Catalyst Pancreatic Lipase Test will be available in the U.S. and Canada this September, with a global rollout to the over 70,000 Catalyst installed base planned to begin in the fourth quarter of 2024.

Pancreatitis is a common disease among cats and dogs, and while treatable, it can prove fatal if not caught early. Diagnosing pancreatitis can be difficult due to its nonspecific symptoms and subtle clinical signs, including vomiting and weight loss, which are among the 10 most frequently recorded clinical signs in primary care clinics.1 Now, with the Catalyst Pancreatic Lipase Test, veterinarians can receive quantitative results in under 10 minutes. By delivering quantitative diagnostic insights during the patient visit, the new test empowers veterinarians to confidently confirm or rule out pancreatitis and immediately begin treatment, saving crucial time and improving patient outcomes.

“The Catalyst Pancreatic Lipase Test marks the tenth menu addition launched for the Catalyst platform since 2012, reinforcing our commitment to extend the clinical value and diagnostic capabilities of our technologies,” said Jay Mazelsky, President and Chief Executive Officer of IDEXX. “We are pleased to deliver a highly requested test, which will streamline the diagnostic workflow and equip veterinarians with the necessary clinical insights for prompt action.”

The Catalyst Pancreatic Lipase Test, coupled with VetConnect® PLUS software, provides a critical solution for the long-term management of pancreatitis patients due to the chronic nature of the disease. VetConnect PLUS allows for seamless integration of historical data and test results, enabling efficient patient progress evaluation and treatment response.

“The Catalyst Pancreatic Lipase Test is the first test to use dry chemistry slide technology that specifically measures pancreatic lipase and correlates with the IDEXX Reference Laboratories Spec cPL® and Spec fPL® tests* to provide the most accurate, quantitative results patient-side for dogs and cats,” said Jörg M. Steiner, Dr.med.vet., PhD, DACVIM-SA, DECVIM-CA, AGAF, Texas A&M University.†

New Catalyst SmartQC Control
In the fourth quarter of 2024, the Catalyst platform will be further enhanced with the launch of the Catalyst® SmartQC® Control, a load-and-go quality control testing system that is 90% faster than current methods.2 The Catalyst SmartQC Control offers an intuitive workflow that takes less than 15 minutes, ensuring quality control is run consistently without compromising staff productivity. These enhancements will be delivered through IDEXX SmartService™ Solutions, a cloud-based software that supports in-house instruments and powers seamless upgrades for new tests and features.

Please visit idexx.com for more information on the Catalyst Pancreatic Lipase Test and Catalyst SmartQC Control.

About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” “project,” and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

1Robinson NJ, Dean RS, Cobb M, Brennan ML. Investigating common clinical presentations in first opinion small animal consultations using direct observation. Vet Rec. 2015;176(18):463. doi:10.1136/vr.102751
*The Spec cPL Test for dogs and the Spec fPL Test for cats measure the level of pancreas-specific lipase in the blood: www.idexx.com/en/veterinary/reference-laboratories/pancreatic-health.
†Dr. Steiner has received compensation from time to time for consulting services he has provided to IDEXX.
2Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA.

View original content to download multimedia:https://www.prnewswire.com/news-releases/idexx-expands-test-menu-for-the-catalyst-platform-to-support-veterinarians-globally-in-diagnosing-pancreatitis-302162411.html

SOURCE IDEXX Laboratories, Inc.

Continue Reading

Technology

Global Product Placement Spending Grew 12.7% in 2025 to $37.2B & Pacing for Faster Growth Again in 2026, Driven by TV, Film, Music & Digital Media

Published

on

By

Global product placement spending grew 12.7% in 2025 to $37.16 billion, accelerating from the 12.1% gain posted in 2024, fueled by double-digit growth in TV, film, music and digital media, which benefited from the end of writer and actor strikes in the US opening up production schedules and launching a cavalcade of new content, according to new PQ Media research released today.

STAMFORD, Conn., Oct. 7, 2026 /PRNewswire-PRWeb/ — Global product placement spending grew 12.7% in 2025 to $37.16 billion, accelerating from the 12.1% gain posted in 2024, fueled by double-digit growth in TV, film, music and digital media, which benefited from the end of writer and actor strikes in the US opening up production schedules and launching a cavalcade of new content, according to new PQ Media research released today. Product placement spending worldwide is on pace to grow at a faster rate of 12.8% in 2026 to $41.92 billion, marking the sixth consecutive year of double-digit growth, following the worst decline ever in pandemic-struck 2020, per PQ Media’s 11th edition Global Product Placement Forecast 2026-2030.

Paid product placements have grown substantially over the past 25 years because brands have become more willing to invest in skillful integrations of their logos and products in storylines that will expose their assets in meaningful ways.

In the US, which accounted for 56.5% of the global market for product placement in all media, total spending rose 13.2% in 2025 to $21.01 billion, faster than the 12.3% gain in 2024. Brazil, Mexico and Australia were the only other countries to generate more than $1 billion in product placement spending in 2025. The Netherlands was the fastest-growing market in 2025, rising 16.3%, while the United Kingdom was the only other top-20 market to rise by more than 15% for the year. In total,19 of the 20 top-20 global markets generated double-digit growth in 2025, with the exception of Russia.

In the 11th edition of the Global Product Placement Forecast 2026-2030, PQ Media found that the impact of the pandemic and writer/actor strikes in the United States are now in the rear window and the industry is growing annually at double-digit rates worldwide and will continue to do during the 2026-2030 forecast period.

Driving growth in 2025 was the continuing shift to streaming content, particularly television shows and movies being produced by the streaming video subscription services in each of the top-20 markets. Additionally, micro-dramas, short 5-15 minute episodic clips from an ongoing series on social media sites, have benefitted significantly from product integrations. Artificial intelligence has helped drive growth in digital media, videogame and music video product placements. Meanwhile, PQ Media found that print media are accepting more product placements to compensate for the declining ad revenues suffered over the last two decades.

But there is concern among product placement professionals that the opportunities for product integrations are slowing. Broadcast and cable TV networks are producing fewer new scripted and reality programs. Movie studios have yet to exceed the number of films produced in 2019. Videogame publishers are holding off releasing new titles until the new console upgrades in 2027 or 2028. Print magazines are folding and newspapers are shuttering print editions. Fewer music videos are being produced and there is a slowdown in new podcasting titles.

“Despite these concerns, content publishers have become more willing to include product integrations in all media to help deal with rising production costs,” said PQ Media President & CEO Patrick Quinn, “Additionally, paid product placements have grown substantially over the past 25 years because brands have become more willing to invest in skillful integrations of their logos and products in storylines that will expose their assets in meaningful ways. This trend will continue going forward. due to the popularity of this marketing tactic among the younger demographics that the brands are targeting.”

Product placement in TV remains, by far, the largest media platform category worldwide, valued at $26.16 billion in 2025. The hottest streaming TV series are driving the double-digit growth in product placement in the overall TV category, such as the brand integrations in “The Hawk” on Netflix. Meanwhile, movie integrations, the second largest platform category, generated $4.44 billion globally last year, with many of the integrations being included in top grossing films, such as “Spider-Man: Brand New Day.” which had 165 brand partnerships which was reportedly valued at over $300 million.

Product placement in music was the fastest-growing placement category in 2025, rising 13.8%, fueled by product placements in popular podcasts, particularly those in which the host references the brands and products. TV integrations ranked second in growth, followed by digital media product placements, as virtual placements (adding a brand in post-production when a theatrical film is shown on a streaming video service), and AI-embedded integrations are becoming more commonplace. The print media and videogame categories were the only channels not to post double-digital gains in 2025.

About the Report:

PQ Media’s Global Product Placement Forecast 2026-2030, the 11th edition of the industry’s recognized performance benchmark, is the only source to consistently define, size, analyze and project the growth of product placement spending in media. The new edition has expanded to cover 6 major media platforms and 19 media channels across all top 20 global markets. Below is a breakdown of the report’s expanded coverage of media platforms and channels:

Television/Video – Broadcast TV, Cable TV, Streaming TV;Filmed Entertainment – Theatrical Films, Streaming Films;Digital Media – Pure-Play Digital Sites, Social Media & Blogs, Virtual Placements & Artificial Intelligence, Influencer Sites;Videogames – Console/PC Games, Mobile Games, Internet Games;Print Media – Print & Digital Magazines, Newspapers, Books;Recorded Music – Music Videos, Broadcast & Streaming Radio, Podcasts, Lyrics

The Core PDF Report & Analysis delivers 259 slides of exclusive market data and insights, which is enhanced by the Deep-Dive Excel Databook that provides 5,625 datasets and over 250,000 datapoints by country, media platform and channel, covering the 2020-2030 period with five-year forecasts, exclusive rankings of the largest and fastest growing media platforms and global markets, and in-depth profiles of each major country. To Download a Free Executive Summary and Sample Datasets click: Global Product Placement Forecast 2026-2030.

About PQ Media:

PQ Mediadelivers strategic intelligence, data and analysis to the world’s leading media, entertainment and technology organizations through syndicated market intelligence reports, custom drill-down research services, and on-demand strategic consulting. PQ Media uses a proprietary econometric methodology to define, segment, size, analyze and project the growth of several hundred traditional, digital and alternative media by country, platform, channel and demographic. PQ Media also publishes the annual Global Media Forecast Series 2026 (13th edition), with each report covering one of the three industry KPIs – Advertising & Marketing Spending; Consumer Media Usage & Exposure; and Consumer Spending on Media Content & Technology.

Media Contact

Patrick Quinn, PQ Media, 1 203-921-5249, pquinn@pqmedia.com, https://www.pqmedia.com

Leo Kivijarv, PQ Media, 1 203-273-7081, lkivijarv@pqmedia.com, https://www.pqmedia.com

View original content to download multimedia:https://www.prweb.com/releases/global-product-placement-spending-grew-12-7-in-2025-to-37-2b–pacing-for-faster-growth-again-in-2026–driven-by-tv-film-music–digital-media-302900751.html

SOURCE PQ Media

Continue Reading

Technology

/R E P E A T – Media Advisory – Minister Hodgson to deliver keynote at Global Risk Institute Summit/

Published

on

By

TORONTO, Oct. 5, 2026 /CNW/ — The Honourable Tim Hodgson, Minister of Energy and Natural Resources, will make a keynote address at the Global Risk Institute’s Summit 2026. Open to the media.

Date: Wednesday, October 7, 2026

Time: 10 a.m. ET

All accredited media are asked to register with GRI Summit 2026. Details on how to participate will be provided upon registration.

Follow Natural Resources Canada on LinkedIn.

SOURCE Natural Resources Canada

Continue Reading

Technology

MintNeuro raises $5 million to scale purpose-built chip platform for neural devices and brain-computer interfaces

Published

on

By

Funding from European and US investors will accelerate product launch,
partner adoption and international expansion

LONDON, Oct. 7, 2026 /PRNewswire/ — MintNeuro, a semiconductor company building specialised chips for neural devices from implants to wearables, today announces a $5 million investment round to drive its commercial scale-up. MintNeuro’s chips give device developers better performance than generic components, with less risk, lower cost and a faster route to market than custom chip design. The funding will accelerate product launch, expand delivery of pre-release silicon to partners and grow the company’s international presence.

The round was led by Odyssey Ventures, with participation from 33East, JSK Investments and Alumni Ventures, and returning investment from Empirical Ventures, Jumpspace Ventures and early investors. Bringing together deep tech, medtech and early-stage investors across Europe and the US, the round reflects global demand for the hardware needed to scale neurotechnology.

MintNeuro has already delivered working silicon and reached key integration milestones with research and development partners, including Motif Neurotech and Amber Therapeutics. Earlier this year, MintNeuro announced a partnership and multi-year commercial chip supply agreement with Motif, supporting the development of Motif’s minimally invasive neurostimulator initially targeting treatment-resistant depression. A growing number of neural device companies are now evaluating or integrating MintNeuro’s technology, alongside research teams building implantable systems that connect directly to the brain and nervous system.

MintNeuro will use the investment to grow its engineering and commercial teams, bring its products to market, support customers as they adopt its chips and strengthen its presence in the US alongside its UK and European base.

Neural devices are opening new ways to understand and treat conditions across neurology, mental health and beyond, from Parkinson’s disease, epilepsy and depression to hearing loss and inflammatory disease. These technologies include brain-computer interfaces (BCIs), neuromodulation systems, sensory prostheses and bioelectronic medicines. Until now, progress across the industry has been held back by the lack of standard chips designed specifically for the extreme power, size, safety and signal-quality demands of these devices.

MintNeuro is closing that gap with a modular semiconductor platform purpose-built for core functions like neural sensing, signal processing and stimulation: listening to the body’s nerve signals, interpreting them, and delivering precise electrical pulses to treat disease or restore function. Instead of adapting generic components or funding years of custom chip design, developers can build on MintNeuro’s chips to create smaller, lower-power neural devices and move from research to clinical use sooner.

MintNeuro’s modular architecture provides the building blocks to combine sensing, processing and stimulation efficiently at the system level, supporting more integrated closed-loop interfaces with the nervous system.

Commenting on the investment, Dorian Haci, Co-Founder and CEO of MintNeuro, said: “Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development. We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on.”

Michelle Robson, Founding Partner at Odyssey Ventures, said: “Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption. MintNeuro has the technology, market pull and ambition to become a globally important semiconductor company, and we are backing this exceptional team as it scales from the UK into global markets, including Silicon Valley.”

Yiannis Eftychiou, Co-Founder and Partner at 33East, said: “What stood out to us is the sheer breadth of the hardware opportunity. MintNeuro is solving critical needs for neural implants today, with technology that can extend into wearables and beyond.”

Johnathan Matlock, Co-Founder and General Partner at Empirical Ventures, said: “We invested before the chips were in hand, and we are reinvesting now that MintNeuro has working silicon, deep customer traction and a clear path to becoming a category-defining semiconductor business.”

Professor Tim Denison, Chair of MintNeuro, added: “Neurotechnology is entering a phase where specialised hardware will determine how far, and how fast, the field can go. MintNeuro’s semiconductor technology is well-placed to remove the key obstacle to industry scale, which could dramatically accelerate the pace of innovation.”

About MintNeuro (www.mintneuro.com)

Founded as a spinout from Imperial College London, MintNeuro is building the semiconductor foundation for the next generation of neurotechnology. The company develops specialised chips that enable devices to connect with the brain and nervous system, helping innovators create new therapies for neurological and mental health conditions.

As neurotechnology moves from research labs into clinical and commercial deployment, MintNeuro is addressing one of the sector’s most critical challenges: providing a scalable semiconductor platform designed specifically for neural devices. By removing the need for custom chip development or adapted generic components, MintNeuro aims to accelerate innovation, reduce development barriers and help bring transformative neurotechnology products to market faster.

The company works with leading developers, researchers and medical device companies, with a long-term vision to become the industry-standard semiconductor platform powering the future of brain-computer interfaces, bioelectronic medicine and other technologies that connect humans and machines.

MintNeuro’s immediate focus is medical applications, where size, power, reliability and safety are critical. The same core technology has the potential to become the chip layer for any device that connects to the brain and nervous system, providing the interface between human biology and the digital world.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mintneuro-raises-5-million-to-scale-purpose-built-chip-platform-for-neural-devices-and-brain-computer-interfaces-302900235.html

SOURCE MintNeuro

Continue Reading

Trending